Breaking News

Johnson & Johnson Acquires TARIS Biomedical

TARIS will maintain a research presence in Lexington, MA and become part of Janssen R&D's Oncology Therapeutic Area

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson has acquired TARIS Biomedical LLC, a privately-owned biotechnology company specializing in novel drug delivery technology for the treatment of bladder diseases, including cancer. The company’s lead clinical-stage product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder. Financial terms were not disclosed.        “The TARIS technology provides ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters